The SBS3 HR deficient signature has previously been associated with HRD and germline and somatic BRCA1 and BRCA2 mutations and BRCA1 promoter methylation in breast [53], pancreatic [54] and ovarian [23] cancers. This evidence concerns the gene BRCA1 and cancer.